Info

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice. All medication decisions should be made in consultation with your licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

The Core Question

If you are considering RNK Health and have reached the point of choosing between compounded semaglutide and compounded tirzepatide, you are asking the right question. These are not equivalent medications — they work through different mechanisms, have different clinical trial profiles, and carry different price points within RNK Health's program structure. This article gives you the verified information needed to have a productive conversation with the physician who reviews your case. It does not make the choice for you. That is your physician's job.

For a full assessment of how RNK Health's program works, including coaching structure and pharmacy details, see the complete RNK Health review. For foundational context on what compounded GLP-1 medications are, see our plain-language GLP-1 explainer.

The Mechanism Difference: One Receptor vs. Two

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors — found in the pancreas, stomach, brain, liver, and other tissues — and activates the same signaling pathways that the body's naturally produced GLP-1 hormone activates. The effects include increased insulin secretion in response to glucose, reduced glucagon release, slowed gastric emptying, and reduced appetite through central nervous system signaling at the hypothalamus and brainstem.

Tirzepatide adds a second mechanism. It is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. GIP is another incretin hormone produced in the gut in response to food, with roles in insulin secretion, fat metabolism, and — when its receptor is activated pharmacologically in combination with GLP-1 — potentially enhanced effects on appetite regulation and energy balance. In simple terms: semaglutide works through one hormonal lock; tirzepatide works through two simultaneously.

The clinical significance of that second mechanism is not just theoretical — it showed up clearly in phase 3 trial data. But trial comparisons require careful interpretation, which the next section addresses.

What the Phase 3 Trials Show (and What They Don't)

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) was a randomized, double-blind, placebo-controlled trial of 68 weeks in 1,961 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received semaglutide 2.4 mg weekly plus lifestyle intervention or placebo plus lifestyle intervention. The semaglutide group lost an average of 14.9% of body weight from baseline; the placebo group lost 2.4%. This is peer-reviewed efficacy data for FDA-approved Wegovy at its approved dose.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) was a randomized, double-blind, placebo-controlled trial of 72 weeks in 2,539 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo — all combined with lifestyle intervention. Average weight loss was 15.0%, 19.5%, and 20.9% at the respective tirzepatide doses, versus 3.1% in the placebo group. This is peer-reviewed efficacy data for the active ingredient in FDA-approved Zepbound.

The critical interpretive point: these are two separate trials with similar but not identical patient populations, different trial durations, and different doses. They are not a head-to-head comparison. In the only direct head-to-head trial between the two molecules in type 2 diabetes patients (SURPASS-2, published in New England Journal of Medicine 2021), tirzepatide at all doses produced greater weight reduction than semaglutide 1 mg — but the weight loss indication uses a different (higher) semaglutide dose than was studied head-to-head. The takeaway is directional: tirzepatide's dual mechanism appears to produce greater average weight loss in clinical trials. The exact magnitude of that difference in a given patient is unknowable in advance.

Both sets of trials used brand-name, FDA-approved formulations — not compounded versions. No peer-reviewed trials have independently validated equivalent outcomes for compounded semaglutide or tirzepatide specifically. This is a scope caveat that applies to every compounded GLP-1 program, not just RNK Health's.

Pricing Within RNK Health's Program

At RNK Health, as of publication:

Injectable semaglutide: $197/month all-inclusive (medication, physician oversight, coaching, supplies, shipping). Oral semaglutide: $198/month all-inclusive. Injectable tirzepatide: $297/month all-inclusive.

The tirzepatide premium within RNK Health's program is $100/month over injectable semaglutide — $1,200/year. That is not a trivial sum, and it is a legitimate factor to weigh against the clinical profile difference. Whether that premium is appropriate for a given patient depends on their health history, starting BMI, comorbidities, prior treatment history, and physician recommendation. A provider who recommends tirzepatide for a patient with significant insulin resistance and type 2 diabetes is operating differently than one who recommends it as a first-line option for a patient with modest weight to lose. These are clinical judgments, not consumer choices.

The Oral Semaglutide Question

RNK Health's oral semaglutide option ($198/month) deserves separate examination. The FDA-approved oral semaglutide tablet (Rybelsus, approved for type 2 diabetes, not for weight management) uses a proprietary absorption enhancer — SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — that enables meaningful bioavailability of semaglutide when taken orally, under specific conditions (fasting, small amount of water, 30 minutes before food). Most compounded oral semaglutide formats — including dissolving tablets and lozenges — do not incorporate this technology.

What this means practically: the bioavailability of compounded oral semaglutide is not established by peer-reviewed pharmacokinetic studies. It may be lower than injectable compounded semaglutide. Patients who prefer to avoid injections should ask their physician specifically about the evidence base for the oral compounded format relative to the injectable option before choosing it on the basis of needle aversion alone. There may be an appropriate patient for oral compounded semaglutide — but that patient should make the choice with accurate information about the bioavailability question.

Questions to Bring to Your Physician Review

The RNK Health intake process ends with a licensed physician determining your eligibility and the appropriate medication. Making that conversation productive requires you to show up with the right questions. Based on the clinical landscape and the distinguishing features of these two options, the most useful question is: Do my comorbidities (if any) favor one mechanism over the other? Is my starting BMI or weight loss target one where the tirzepatide data's higher average weight loss is clinically meaningful for my situation, or is the semaglutide data's profile sufficient? Are there any elements of my medical history that make one option preferable or one a relative contraindication? Given my goals and history, does the $100/month cost difference favor starting with semaglutide and escalating only if response is insufficient?

These questions turn a prescribing encounter into a clinical conversation. They are also the questions that will tell you whether the physician reviewing your case is genuinely engaging with your history or running through a standardized algorithm. Both are informative.

Side Effects: Are They Different Between the Two?

Both semaglutide and tirzepatide share a common side effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose escalation. These effects typically improve over time as the body adjusts. Injection site reactions are possible with injectable formulations of both medications.

The side-effect profiles are similar because both medications activate GLP-1 receptors—the mechanism responsible for most GI effects. Tirzepatide's additional GIP receptor activation does not appear to substantially alter the side-effect profile, though individual tolerability can vary. For a complete, dedicated guide to side effects, contraindications, and safety monitoring for RNK Health's programs, see our RNK Health safety and side effects guide.

Frequently Asked Questions

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one receptor pathway (GLP-1); tirzepatide activates two (GLP-1 and GIP). Phase 3 trial data shows tirzepatide produced greater average weight loss at its highest studied dose, though these were separate trials — not a direct head-to-head comparison in weight management populations.

Is tirzepatide better than semaglutide for weight loss?

In separate phase 3 trials, tirzepatide at 15 mg weekly produced average weight loss of approximately 20.9% over 72 weeks (SURMOUNT-1), while semaglutide at 2.4 mg weekly produced approximately 14.9% over 68 weeks (STEP-1). These were separate trials, not direct head-to-head comparisons. Individual response and tolerability vary.

Which costs more at RNK Health — semaglutide or tirzepatide?

As of publication, injectable semaglutide is $197/month and tirzepatide is $297/month at RNK Health, both all-inclusive. The $100/month difference should be weighed against clinical factors in conversation with your physician.

Can I switch between semaglutide and tirzepatide at RNK Health?

Medication changes require physician guidance. Switching involves restarting titration at a low dose and is a clinical decision based on individual response and goals.

What is the oral semaglutide option at RNK Health?

RNK Health offers oral dissolving semaglutide at $198/month. Most compounded oral formulations lack the SNAC absorption enhancer used in FDA-approved Rybelsus. Patients should ask their physician about bioavailability expectations before choosing the oral format.

How long does it take to see results?

Appetite reduction typically begins within the first weeks. In clinical trials of brand-name formulations, measurable weight loss appeared within four weeks, with most weight loss occurring in the first four to five months. Individual results with compounded versions may differ.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications offered through RNK Health require evaluation by a licensed healthcare provider and have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.

The Short Answer

RNK Health is a telehealth-based weight management and longevity platform. Patients complete an online health assessment, a licensed physician reviews the information and determines whether a prescription is appropriate, and if so, compounded medication is shipped directly to the patient's home. The primary programs involve compounded semaglutide and compounded tirzepatide — two GLP-1 receptor agonist active ingredients with an established body of clinical literature. RNK Health also offers NAD+ and Sermorelin programs for patients interested in broader longevity support.

This article explains what GLP-1 therapy is, how compounded medications differ from brand-name options, how the RNK Health process works, and what prospective patients should understand before starting. For verified pricing and a full program assessment, see our complete RNK Health review.

What Is GLP-1 Therapy?

GLP-1 stands for glucagon-like peptide-1 — a hormone naturally produced in the gut in response to food intake. It plays several roles in metabolic regulation: it stimulates the pancreas to release insulin in response to rising blood glucose, slows gastric emptying (the rate at which food leaves the stomach), and acts on areas of the brain involved in appetite signaling, producing a sense of fullness earlier and for longer than food alone typically achieves.

GLP-1 receptor agonists are medications designed to bind to the same receptors that the body's natural GLP-1 hormone activates, amplifying these effects. They do not stimulate the central nervous system the way older appetite suppressants did. They work through a hormonal pathway, which is why the clinical profile — including the side effect profile — is different from previous generations of weight management medications.

The two active pharmaceutical ingredients RNK Health's programs are built around — semaglutide and tirzepatide — are the same ingredients in the brand-name FDA-approved medications Wegovy (semaglutide, approved for chronic weight management), Ozempic (semaglutide, approved for type 2 diabetes), Zepbound (tirzepatide, approved for chronic weight management), and Mounjaro (tirzepatide, approved for type 2 diabetes). The distinction between the brand-name and compounded versions matters and is explained below.

What Does “Compounded” Mean?

Pharmaceutical compounding is the practice of a licensed pharmacist preparing a customized medication for an individual patient based on a licensed prescriber's order. Compounding has a recognized place in medicine — it allows access to medications in formulations or doses that are not commercially available, for patients with allergies to inactive ingredients in commercial products, or when commercial products are unavailable.

Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredients as the brand-name versions. What they do not have is FDA approval as finished drug products. This means they have not undergone the FDA's review process for safety, effectiveness, or manufacturing quality as a finished formulation. They are prepared by state-licensed compounding pharmacies under requirements established by state pharmacy boards and, for outsourcing facilities (503B pharmacies), by FDA oversight as well.

This distinction is not a reason to categorically avoid compounded GLP-1 medications — it is a reason to understand exactly what you are taking and to ensure the compounding pharmacy involved operates to high standards. The questions to ask a compounding pharmacy before starting are: What is your 503A or 503B designation? Are you on the FDA's registered outsourcing facilities list? Do you test finished product for potency and sterility? An operation with transparent answers to all three is meaningfully different from one that is evasive.

RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. Patients can use this address to look up the pharmacy's registration status with the Utah Division of Professional Licensing and the FDA's outsourcing facility database.

How Does the RNK Health Process Work?

The intake process is fully online. Patients complete a digital health questionnaire covering their medical history, current medications, weight history, and treatment goals. A licensed physician reviews this information and determines whether a prescription for compounded semaglutide or tirzepatide is clinically appropriate. Patients who do not meet prescribing criteria are not approved — which is how a medically responsible program operates.

If a prescription is issued, RNK Health states that medication is compounded and shipped within 48 hours to the patient's address via private home delivery. All plans include the medication itself, the physician consultation and prescription management, personal coaching, required self-administration supplies (syringes and alcohol swabs for injectable formulations), and shipping — with no separately billed fees. Plans are month-to-month with no long-term contract.

Patients seeking the most detailed comparison of semaglutide and tirzepatide within the RNK Health context — including mechanism differences, trial data, and how to think about which option to discuss with a provider — should read our semaglutide vs. tirzepatide guide for RNK Health patients.

Who Qualifies?

GLP-1 receptor agonist therapy for weight management is generally evaluated for adults who meet specific BMI criteria. Standard prescribing thresholds — consistent with the FDA-approved indications for Wegovy and Zepbound — include adults with a BMI of 30 or greater (classified as obesity), or adults with a BMI of 27 or greater (classified as overweight) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.

These thresholds are guidelines, not guarantees. The prescribing decision belongs entirely to the licensed physician who reviews your specific intake information. Certain medical histories are standard contraindications that a reviewing physician will evaluate: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, severe gastrointestinal conditions, current or planned pregnancy, and end-stage kidney or liver disease, among others.

Full disclosure of your medical history during the intake process is not optional — it is the mechanism by which the platform ensures the medication is appropriate for you. Incomplete disclosure creates risk. Complete disclosure allows the physician to make an informed determination, and in some cases, to recommend a different treatment approach.

What Is NAD+ and How Does It Fit?

RNK Health's NAD+ offering sits in a different category from its GLP-1 programs. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function. Research on NAD+ supplementation in humans is an active and developing area; while preclinical and early-phase human studies show interesting signals around aging and metabolic function, large-scale randomized controlled trials establishing definitive clinical outcomes are still limited. Patients interested in NAD+ should review the current evidence with their healthcare provider and approach the category as an emerging area of inquiry rather than an established therapeutic intervention.

RNK Health offers NAD+ starting at $129/month in injectable, nasal spray, and liposomal liquid formats, giving patients format flexibility based on preference and comfort with self-administration.

The Bottom Line on What RNK Health Is

RNK Health is a telehealth platform that provides physician-supervised access to compounded GLP-1 medications — the same active ingredients as brand-name Wegovy and Zepbound — at a fraction of the brand-name price, with personal coaching included at no additional cost and a disclosed U.S.-based pharmacy. It is not a supplement program, not an over-the-counter solution, and not a substitute for a primary care relationship. It is a prescription telehealth service that operates within a recognized medical framework, with the attendant requirements that implies: a licensed prescriber, a licensed pharmacy, and patient responsibility for accurate medical disclosure.

For a complete program assessment including verified pricing, coaching details, and our editorial conclusions, see the RNK Health review. For safety considerations, contraindications, and what to watch for during treatment, see our RNK Health side effects and safety guide.

Frequently Asked Questions

What is RNK Health?

RNK Health is a telehealth platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 weight management medications — primarily compounded semaglutide and compounded tirzepatide — along with longevity therapies including NAD+. Available in all 50 states.

What does compounded mean for GLP-1 medications?

Compounded GLP-1 medications contain the same active pharmaceutical ingredient as brand-name versions but are prepared by a licensed compounding pharmacy. They are not FDA-approved as finished drug products and require a prescription from a licensed healthcare provider.

How does the RNK Health intake process work?

Patients complete a digital health assessment. A licensed physician reviews it and determines whether a prescription is appropriate. If approved, medication ships to the patient's address within approximately 48 hours of physician approval.

Who qualifies for GLP-1 therapy at RNK Health?

Standard GLP-1 prescribing criteria include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater with at least one weight-related comorbidity. Final eligibility is determined by the reviewing licensed physician.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. RNK Health's programs involve compounded prescription medications that require evaluation by a licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.

What Is RNK Health?

RNK Health (myrnk.com) is a telehealth-based weight management and longevity platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 medications — primarily compounded semaglutide and compounded tirzepatide — along with wellness therapies including NAD+ and Sermorelin. The model mirrors the growing category of online-first GLP-1 clinics: patients complete a digital health assessment, a licensed physician reviews the information and determines eligibility, and if a prescription is appropriate, medication is compounded at a licensed U.S. pharmacy and shipped directly to the patient's door.

What distinguishes RNK Health from many competitors in this space is the inclusion of a dedicated personal coach at no additional cost with every plan. In a market where coaching is often a premium add-on—or absent entirely—this bundled structure is worth honest examination, which this review does. We cover the program structure, verified pricing, medication options, pharmacy transparency, and the key questions any informed patient should ask before starting.

For a broader overview of what compounded GLP-1 medications are and how they differ from FDA-approved brand-name options, see our educational primer on RNK Health and compounded GLP-1 therapy.

What Medications Does RNK Health Offer?

RNK Health's primary treatment offerings involve the two most-studied GLP-1 active pharmaceutical ingredients in the weight management category: semaglutide and tirzepatide. Both are available only through a licensed provider evaluation, not over the counter.

Compounded semaglutide (injectable): Semaglutide is a GLP-1 receptor agonist — meaning it binds to the same receptor as the body's naturally occurring glucagon-like peptide-1 hormone, which plays a role in appetite signaling, gastric emptying rate, and insulin regulation. The FDA-approved injectable forms of semaglutide for chronic weight management are Wegovy (2.4 mg weekly) and Ozempic (approved for type 2 diabetes, sometimes prescribed off-label for weight management at a clinician's discretion). RNK Health's compounded semaglutide contains the same active pharmaceutical ingredient but is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer — an important distinction covered in detail below.

Compounded semaglutide (oral dissolving): RNK Health also offers an oral semaglutide format. Oral administration of semaglutide raises pharmacokinetic considerations worth understanding. The FDA-approved oral semaglutide tablet (Rybelsus) uses a specialized absorption enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC) to achieve meaningful bioavailability. Most compounded oral semaglutide formulations — including oral dissolving tablets and lozenges — do not use this technology, and independent pharmacokinetic data on their absorption characteristics is limited. Patients considering oral compounded semaglutide should discuss expected bioavailability with their provider.

Compounded tirzepatide (injectable): Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Where semaglutide targets one receptor, tirzepatide targets two. In the SURMOUNT-1 randomized controlled trial — a peer-reviewed study published in the New England Journal of Medicine — participants without diabetes taking tirzepatide at 15 mg weekly lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% in the placebo group. FDA-approved tirzepatide for weight management is marketed as Zepbound (15 mg maximum weekly dose) and for diabetes as Mounjaro. RNK Health's compounded tirzepatide contains the same active ingredient in compounded form.

NAD+ and Sermorelin: RNK Health also offers NAD+ (nicotinamide adenine dinucleotide) supplementation starting at $129/month in injectable, nasal spray, and liposomal formats, as well as Sermorelin, a growth hormone releasing hormone analog. These fall outside the GLP-1 category and are not the primary focus of this review. Patients interested in these programs should discuss the evidence base and their individual suitability with a licensed provider.

Verified Pricing (as of Publication)

Pricing transparency is a legitimate differentiator in the GLP-1 telehealth space, where hidden fees and membership tiers are common. Based on publicly available information reviewed by our editorial team, RNK Health's published pricing structure is as follows:

Injectable semaglutide: $197/month, all-inclusive. Oral semaglutide: $198/month, all-inclusive. Injectable tirzepatide: $297/month, all-inclusive. All plans include medication, licensed physician consultation and prescription management, personal coaching, required supplies (syringes, alcohol swabs), and shipping. RNK Health states there are no hidden fees and the model is month-to-month with no long-term contract or cancellation penalty.

For context: brand-name Wegovy has a list price above $1,300/month, and brand-name Zepbound starts near $1,086/month at list price. Compounded alternatives from established competitors typically run $197–$399/month for semaglutide and $249–$399/month for tirzepatide, often without coaching included. RNK Health's tirzepatide pricing at $297/month all-inclusive is competitive for a plan that includes active physician oversight and personal coaching. Always verify current pricing directly with RNK Health before enrollment, as telehealth pricing in this category changes frequently.

The Coaching Model: What It Includes and What to Ask

Bundled personal coaching is the element RNK Health emphasizes most prominently. For patients new to GLP-1 therapy, this matters: GLP-1 medications reduce appetite, but long-term outcomes depend substantially on what patients do with that reduced appetite in terms of protein intake, resistance exercise, and behavioral anchoring. A personal coach who communicates with the prescribing physician and monitors progress can, in principle, help prevent common failure modes like muscle loss from inadequate protein intake during a caloric deficit.

What we cannot independently verify: the specific credentials or qualifications of RNK Health's coaches, the frequency and format of coaching touchpoints, or whether coaching interactions are primarily automated, asynchronous messaging, or synchronous calls. These are specific questions patients should ask during or before the intake process. A coaching program that consists of weekly check-in messages is substantively different from one that includes regular video or phone calls with a credentialed dietitian or health coach — and both can be marketed as “personal coaching.”

Pharmacy Transparency: What to Confirm Before Starting

RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. The prescribing medical provider address is listed as 317 Sixth Avenue, Des Moines, Iowa 50309. This level of pharmacy address disclosure is better than many competitors in this space, who provide no pharmacy identification at all.

What patients should confirm directly: whether the pharmacy holds 503A or 503B designation with their state board, whether it appears on the FDA's list of registered outsourcing facilities, and whether it tests finished product for potency and sterility. These questions are reasonable, answerable, and the mark of a transparent compounding operation. A pharmacy that cannot answer them clearly is a pharmacy worth avoiding.

RNK Health states medications ship within 48 hours of physician approval via private home delivery. The program is available across all 50 states.

What the Clinical Evidence Shows About These Medications

It is important to distinguish between the evidence base for the active pharmaceutical ingredients (semaglutide and tirzepatide) and the evidence base for RNK Health as a specific program. The former is substantial. The latter involves no independent peer-reviewed outcomes data — which is true of virtually every telehealth GLP-1 platform, not a specific criticism of RNK Health.

For semaglutide: the STEP-1 randomized controlled trial (Wilding et al., New England Journal of Medicine, 2021) found that adults with obesity without diabetes who received semaglutide 2.4 mg weekly combined with lifestyle intervention lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo plus lifestyle group. For tirzepatide: the SURMOUNT-1 randomized controlled trial (Jastreboff et al., New England Journal of Medicine, 2022) found average weight loss of 15.0%, 19.5%, and 20.9% at tirzepatide doses of 5, 10, and 15 mg respectively over 72 weeks, compared with 3.1% in the placebo group. These trials used brand-name, FDA-approved formulations — not compounded versions. Individual results from compounded products may differ, and no compounded-specific outcome trials have been published as of this writing.

For broader context on how compounded semaglutide compares to tirzepatide specifically within RNK Health's program structure, see our semaglutide vs. tirzepatide decision guide for RNK Health patients.

Who RNK Health May Be Appropriate For

Based on standard GLP-1 prescribing criteria, candidates for GLP-1 receptor agonist therapy typically include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Prescribing decisions rest entirely with the licensed physician who reviews your intake form and health history — not with the platform itself, and not with this article.

RNK Health may not be appropriate for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, current or planned pregnancy, a history of pancreatitis, end-stage kidney or liver disease, or certain other contraindications. Patients should disclose their complete medical history during the intake process. For a complete overview of risk factors and side effects, see our dedicated RNK Health side effects and safety guide.

Our Assessment

RNK Health is a structurally transparent GLP-1 telehealth program in a market that rewards opacity. All-inclusive pricing, a disclosed pharmacy address, 50-state availability, month-to-month flexibility, and bundled coaching at no additional cost are genuine differentiators — not marketing language that dissolves under scrutiny. The oral semaglutide bioavailability question and the coaching credential question are legitimate gaps that informed patients should close before enrolling. Neither is a disqualifying concern; both are questions with answerable answers.

What RNK Health is: a legitimate telehealth pathway to physician-supervised compounded GLP-1 therapy with competitive all-inclusive pricing and an above-average support model for this category. What it is not: a substitute for a comprehensive metabolic evaluation, ongoing lab monitoring, or a relationship with a primary care provider who knows your full health picture. These programs work best when they complement existing medical care — not when they replace it.

To see how RNK Health stacks up directly against other leading GLP-1 telehealth platforms on pricing, coaching, pharmacy transparency, and access to brand-name medications, see our full RNK Health vs. competitors comparison.

Frequently Asked Questions

What medications does RNK Health offer?

RNK Health offers compounded semaglutide in injectable and oral formats, compounded tirzepatide in injectable form, NAD+ therapy, and Sermorelin. All prescription medications require licensed physician evaluation before a prescription is issued.

How much does RNK Health cost?

As of publication, RNK Health's pricing starts at $197/month for injectable semaglutide, $198/month for oral semaglutide, and $297/month for tirzepatide. All plans include medication, physician oversight, personal coaching, supplies, and shipping. Verify current pricing directly with RNK Health.

Is RNK Health available in all states?

RNK Health states it operates in all 50 states. Patients should confirm availability in their specific state during the intake process.

Are RNK Health's medications FDA-approved?

No. RNK Health's GLP-1 medications are compounded. Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products and have not undergone FDA review for safety, effectiveness, or quality. They contain FDA-approved active pharmaceutical ingredients but are prepared by a compounding pharmacy rather than a pharmaceutical manufacturer.

Does RNK Health include coaching?

Yes. RNK Health includes a dedicated personal coach with every plan at no additional cost. Patients should ask about coach credentials, touchpoint frequency, and the format of coaching interactions before enrolling.